Aprea Therapeutics (NASDAQ:APRE) Issues Earnings Results, Beats Estimates By $0.20 EPS

Aprea Therapeutics (NASDAQ:APRE) posted its quarterly earnings results on Tuesday. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.20, Zacks reports. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%.

Aprea Therapeutics Price Performance

Aprea Therapeutics stock traded up $0.01 during midday trading on Tuesday, hitting $2.27. 6,539 shares of the company were exchanged, compared to its average volume of 18,695. The company has a market cap of $12.34 million, a PE ratio of -0.80 and a beta of 0.82. Aprea Therapeutics has a fifty-two week low of $2.15 and a fifty-two week high of $6.80. The company’s fifty day moving average price is $3.15 and its 200-day moving average price is $3.26.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a research note on Wednesday, January 15th.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.